Filing Details
- Accession Number:
- 0001104659-19-045930
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2019-08-14 16:15:21
- Reporting Period:
- 2019-08-13
- Accepted Time:
- 2019-08-14 16:15:21
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1720893 | Bioxcel Therapeutics Inc. | BTAI | Pharmaceutical Preparations (2834) | 821386754 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1733272 | Frank Yocca | C/O Bioxcel Therapeutics, Inc., 555 Long Wharf Drive New Haven CT 06511 | Chief Scientific Officer | No | Yes | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Acquisiton | 2019-08-13 | 6,547 | $8.67 | 8,397 | No | 4 | P | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | P | Direct |
Footnotes
- The price reported in Column 4 is a weighted average price. The shares were acquired in multiple transactions at prices ranging from $8.50 to $8.76, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares acquired at each separate price within the ranges set forth in this footnote.